EDNRA: A Drug Target / Disease Biomarker (G1909)

Target Name: EDNRA

NCBI ID: G1909

EDNRA

EDNRA: A Drug Target / Disease Biomarker

Edgeoncolan (EDNRA) is a drug target and a potential biomarker for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. EDNRA is a small protein that is expressed in the brain and has been shown to play a role in the development and progression of these disorders.

The research on EDNRA began in the 1990s when scientists discovered that the protein was expressed in the brain and was involved in the production of a neurotransmitter called dopamine. Dopamine is a chemical that is involved in the transmission of signals in the brain and is thought to play a role in the development of neurodegenerative disorders.

Since then, researchers have continued to study EDNRA and its potential as a drug target and biomarker. They have shown that EDNRA is involved in the production and regulation of dopamine and that its levels are affected by a variety of factors, including the levels of dopamine in the brain and the presence of certain neurotransmitters.

One of the key advantages of EDNRA as a drug target is its small size. Unlike many other proteins, EDNRA is expressed in the brain at relatively low levels, which makes it easier to study and potential to be developed into a drug. Additionally, because it is primarily expressed in the brain, it is less likely to cause unintended side effects in other parts of the body.

In addition to its potential as a drug target, EDNRA has also been shown to be a potential biomarker for the treatment of neurodegenerative disorders. Studies have shown that levels of EDNRA are affected by a variety of factors, including the levels of dopamine in the brain and the presence of certain neurotransmitters. This makes it a potential indicator of the progression of these disorders and could be used as a diagnostic tool.

Another promising aspect of EDNRA is its potential to be used in combination with other treatments for neurodegenerative disorders. Researchers have shown that EDNRA can be used in conjunction with other drugs, such as dopamine agonists, to enhance the effects of these drugs and potentially slow the progression of the disorders.

While there is still much to be learned about EDNRA and its potential as a drug target and biomarker, the research suggests that it could be a promising new treatment option for a variety of neurological disorders. Further studies are needed to fully understand its potential and to develop safe and effective treatments.

Protein Name: Endothelin Receptor Type A

Functions: Receptor for endothelin-1. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of binding affinities for ET-A is: ET1 > ET2 >> ET3

The "EDNRA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EDNRA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets